' Breakthrough ' : Adjuvant Pembro Ups Survival in Renal Cancer ' Breakthrough ' : Adjuvant Pembro Ups Survival in Renal Cancer

KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news